EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of HBeAg-negative chronic hepatitis B



Treatment of HBeAg-negative chronic hepatitis B



Seminars in Liver Disease 23(1): 81-88



The goals of therapy in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) are to abolish or efficiently suppress viral replication, which represents the main determinant of underlying liver necroinflammation and fibrosis. Currently available agents include interferon-alfa (IFN-alpha), lamivudine, and soon adefovir dipivoxil. A > or = 12-month course of IFN-alpha treatment or retreatment achieves sustained biochemical responses in 15 to 25% of patients with eventual hepatitis B surface antigen (HBsAg) loss and anti-HBs development in a proportion of them. Lamivudine induces initial virologic and biochemical responses in 70 to 90%, but breakthroughs due to lamivudine-resistant mutants accumulate with continuation of therapy and thus only one third of patients may remain in remission after the third year of therapy. Adefovir dipivoxil also achieves on-therapy responses in the majority of cases. Adefovir dipivoxil and entecavir appear to be effective against lamivudine-resistant strains. Many other antiviral agents and immunomodulatory approaches are currently evaluated for CHB, but, besides IFN-alpha, none has yet been convincingly shown to induce sustained off-therapy responses.

(PDF same-day service: $19.90)

Accession: 035980442

Download citation: RISBibTeXText

PMID: 12616453

DOI: 10.1055/s-2003-37584



Related references

Long-term follow up of peginterferon-α-2a treatment of hepatitis B e-antigen (HBeAg) positive and HBeAg negative chronic hepatitis B patients in phase II and III studies. Hepatology Research 46(10): 992-1001, 2015

New perspectives in the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatology 41(6): 1402-1406, 2005

Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom. Value in Health 18(6): 800-809, 2016

Are hepatitis B e antigen (HBeAg)-positive chronic hepatitis B and HBeAg-negative chronic hepatitis B distinct diseases?. Clinical Infectious Diseases 47(10): 1312-1314, 2008

Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients. Jundishapur Journal of Microbiology 8(3): E21444-E21444, 2015

Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. Liver International 30(8): 1115-1122, 2010

Histological Spectrum of Chronic Hepatitis in HBeAg Positive and HBeAg Negative Hepatitis B Virus Infection. Mymensingh Medical Journal 24(4): 679-683, 2016

Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study. Journal of Hepatology 64(2): S598-S599, 2016

The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b. Pakistan Journal of Pharmaceutical Sciences 28(4 Suppl): 1493-1497, 2015

Hepatitis B surface antigen seroconversion in HBeAg negative chronic hepatitis B patient during entecavir treatment. Turkish Journal of Gastroenterology 25 Suppl 1: 272-273, 2015

Are we ready to use the hepatitis B surface antigen level to guide peginterferon treatment in HBeAg-negative chronic hepatitis B?. Hepatology International 7(1): 13-15, 2013

An analysis of clinical features in HBeAg-negative and HBeAg-positive chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 15(6): 428-430, 2007

Reversion from HBeAg negative to HBeAg positive phenotype after interferon therapy for chronic hepatitis B. Hepatology 30(4 PART 2): 601A, 1999

What Should Be the Endpoints of Oral Therapy in HBeAg-positive Versus HBeAg-negative Patients with Chronic Hepatitis B. Current Hepatitis Reports 11(2): 65-69, 2012

Differential plasma microRNA profiles in HBeAg positive and HBeAg negative children with chronic hepatitis B. Plos One 8(3): E58236-E58236, 2013